乙酰肝素酶、碱性成纤维细胞生长因子在胃癌中表达及对血管新生和肿瘤进展的影响

目的：探讨乙酰肝素酶(Hpa)、碱性成纤维细胞生长因子(bFGF)在胃癌组织中表达及其对血管新生和肿瘤生物学行为的影响。方法：应用免疫组化SABC法检测60例胃癌组织中Hpa、bFGF表达及计数肿瘤微血管密度(MVD)。结果：Hpa、bFGF表达和MVD、浸润深度、TNM分期和淋巴结转移有关，且Hpa、bFGF共表达病例有更高MVD与单独一种阳性表达相比。Hpa表达和bFGF表达呈正相关。结论：Hpa、bFGF可加速肿瘤浸润和转移，促进肿瘤间质微血管生成。且Hpa、bFGF在促进肿瘤间质微血管生成方面有协同作用。     

碱性成纤维细胞生长因子与卵巢癌的关系

目的　探讨碱性成纤维细胞生长因子 (basic fibroblast growth factor,b FGF)对卵巢癌细胞增殖、浸润和肿瘤血管生成的影响 ,及 b FGF单克隆抗体 (b FGF monoclonal antibody,b FGF- MAb)的治疗作用。　方法　将人卵巢癌细胞株 SKOV3接种于 2 4孔板 ,加入不同浓度的 b FGF,每日行结晶紫染色后测定光密度 (D4 90 )值 ,绘制细胞生长曲线 ;将 SKOV3细胞团接种于铺设有细胞外基质凝胶的 4孔板 ,每日测定癌细胞在凝胶中的浸润距离 ;建立 SKOV3细胞裸鼠皮下移植瘤模型 ,每周两次分别将 b FGF、b FGF-MAb和生理盐水注射于移植瘤周围 ,8周后测量肿瘤体积 ;对移植瘤组织切片行 因子的免疫组化染色、测定肿瘤内微血管密度 (microvessel density,MVD)。　结果　 b FGF能促进 SKOV3细胞增殖并呈浓度依赖 ,实验第 5天 ,5 ng/ml、10 ng/ml组细胞 D4 90 值是对照组的 1.0 9倍和 1.2 1倍 ;b FGF能促进 SKOV3细胞浸润并呈浓度依赖 (P<0 .0 5 ) ,第 7天 ,5 ng/ml、10 ng/ml组细胞浸润距离分别是对照组的 1.5 3倍和2 .4 5倍 ;b FGF组移植瘤体积和 MVD分别是对照组的 1.80倍和 1.4 6倍 (P<0 .0 5 ) ,b FGF- MAb组移植瘤体积和 MVD分别是对照组的 6 3.7%和 6 2 .8% (P<0 .0 5 )。　结论　b FGF能明显促进卵巢癌细胞的增殖、     

碱性成纤维细胞生长因子与肝素结合性质的研究进展

碱性成纤维细胞生长因子 (ｂａｓｉｃｆｉｂｒｏｂｌａｓｔｇｒｏｗｔｈｆａｃｔｏｒ ,ｂＦＧＦ)是成纤维细胞生长因子 (ｆｉｂｒｏｂｌａｓｔｇｒｏｗｔｈｆａｃｔｏｒｓ ,ＦＧＦｓ)这一大家族的原型成员 ,自 1974年首次从牛垂体中分离ｂＦＧＦ以来[1] ,ＦＧＦ家族的成员目前已增加至 19位[2 ] 。ＦＧＦｓ各成员结构相关、功能相似 ,调节多种细胞的生长、分化、迁移、凋亡 ,此外 ,该家族成员均能结合肝素或硫酸肝素[3 ] 。ｂＦＧＦ和硫酸肝素的结合是它所具有的复杂生化调节机制的基础。肝素和ｂＦＧＦ及其受体三者共同组成复杂的ｂＦＧＦ…     

肝素酶和碱性成纤维细胞生长因子与非小细胞肺癌转移和预后的关系

目的 探讨肝素酶(heparanase)和碱性成纤维细胞生长因子(bFGF)在人非小细胞肺癌(NSCLC)组织中表达的临床意义及其与肺癌转移和预后的关系。方法 采用免疫组织化学、原位杂交和Western blot方法,检测115例人NSCLC石蜡切片和45例新鲜肺癌及对应癌旁正常组织中肝素酶和bFGF的表达情况。采用χ^2检验、t检验、生存曲线和Cox比例风险回归等方法分析肝素酶和bFGF分别表达及共表达的意义。结果 免疫组织化学染色证实肝素酶(91／115)和bFGF(89／115)主要表达在癌细胞质和(或)细胞膜中,在正常肺泡上皮和支气管上皮中则呈阴性表达。Western blot也证实肝素酶在肺癌中的表达明显增高(P=0．041)。统计分析结果显示：肝素酶和bFGF的表达具有明显的一致性(P：0．0001),二者单独表达和共表达均与肺癌的分期、血管侵袭、淋巴结转移、微血管密度和预后有关,其中,二者共表达时与分期和微血管密度的相关性更显著;另外,bFGF还与肺癌的分化程度有关。多因素分析结果显示,肺癌的分化程度、血管浸润、淋巴结转移和bFGF的表达可以作为判断肺癌预后的危险因素,但肝素酶不是影响预后的独立因素。结论 肝素酶和bFGF均与肺癌的转移、血管生成和预后密切相关。     

碱性成纤维细胞生长因子的研究进展

bFGF是一种作用广泛的细胞因子，其最显著的作用是促进细胞分裂，因此在肿瘤的发生发展、促进损伤组织修复等方面受到关注。除了通过经典的受体途径发挥作用外，高分子量bFGF还具有核转位现象，其核转位只发生在G1-S过渡期。应用酵母双杂交系统发现了能与bFGF发生相互作用的蛋白质，为研究bFGF作用的分子机制提供了有益的线索。     

碱性成纤维细胞生长因子的生物活性分析

本文报告以人脐带内皮细胞原代培养技术,CAM及多聚物载体技术检测bFGF生物活性,结果表明bFGF是机体血管新生的强烈刺激剂。bFGF对血管、神经、结缔组织、骨与软骨细胞具有多向作用,深入研究其生物效应,对于促血管新生,动脉硬化及肿瘤防治,中枢神经创伤后修复,肢体再生,晶体再生,促创伤愈合,以及人工血管的开发应用等均具有重要的实际意义。     

碱性成纤维细胞生长因子对瘢痕成纤维细胞生物学行为的影响

目的探讨碱性成纤维细胞生长因子（bFGF）对瘢痕成纤维细胞生物学特性的影响。方法采用细胞培养、MTT、ELISA法、氯胺T和RT—PCR法检测bFGF在不同作用剂量下对瘢痕来源的成纤维细胞生长增殖和细胞外基质（ECM）合成的影响。结果（1）MTT检测bFGF对瘢痕成纤维细胞有明确的促增殖作用，并具有剂量相关性；（2）氯胺T法显示实验组和对照组HPr含量无显著性差异，RT—PCR法显示各组Ⅰ、Ⅲ型胶原蛋白mRNA表达水平无明显变化；说明bFGF对瘢痕成纤维细胞胶原蛋白的合成无促进作用；（3）ELISA法表明随着bFGF作用浓度的升高，FN的表达表现为增高趋势，且以100ng／ml浓度下作用最显著。结论bFGF可以促进创面愈合，但不引起瘢痕的过度形成。     

血管内皮生长因子和碱性成纤维细胞生长因子在急性白血病患儿血清中的表达及意义

目的:探讨血管内皮生长因子(VEGF)和碱性成纤维细胞生长因子( bFGF)急性白血病(AL)患儿血清中的表达及其与临床意义.方法:采用ELISA方法检测40例初治AL患儿化疗前及治疗1疗程后37例患儿和40例健康儿童血清中VEGF和bFGF的水平.结果:治疗前,AL组以及ALL组、ANLL组血清VEGF和bFGF水平均显著高于对照组(P＜0.05),而血清VEGF和bFGF水平在AL不同类型之间差异无统计学意义(P＞0.05).治疗前,AL缓解(CR)和未缓解(NR)患儿血清VEGF和bFGF水平差异无统计学意义;治疗后,CR患儿血清VEGF和bFGF水平显著下降,与治疗前和NR患儿比较均有显著性差异(P＜0.05);而NR患儿治疗前后血清VEGF和bFGF水平差异无统计学意义.结论:VEGF和bFGF在AL患儿血清中呈高表达,血清VEGF和bFGF水平可作为AL患儿疗效观察指标,并且与患儿的预后有关.     

碱性成纤维细胞生长因子骨诱导作用的研究进展

介绍碱性成纤维细胞生长因子对骨干细胞、成骨细胞、破骨细胞和血管形成的可能作用机理，及其与其它生长因子之间的相互作用。对碱性成纤维细胞生长因子骨诱导作用的研究进展进行综述。     

双抗体夹心ELISA检测碱性成纤维细胞生长因子

碱性成纤维细胞生长因子（basic fibroblast growth factor, bFGF）分布于几乎所有来源于中胚层和神经外胚层的组织中, 等电点9.6, 是相对分子质量（Mr）为18 000的单亚基多肽.bFGF在促进血管生成、创伤愈合、骨骼修复、神经营养与修复、眼晶体再生以及胚胎的发育与分化方面均显示出生物学活性[1, 2], 其生产和应用过程中需要高灵敏度的定量检测方法.1992年本室用鼠抗bFGF多克隆抗体（pAb）在国内首次建立了bFGF间接ELISA检测方法[3], 已经应用于bFGF生产过程中的质控和定量检测以及科学研究等工作.在此基础上, 用本室制备的bFGF单克隆抗体（mAb）与抗bFGF酶标pAb, 建立了bFGF双抗体夹心ELISA方法, 并对其重复性、精密度和适合性做了分析, 为bFGF的定量检测提供了有效的手段.……     

Inhibition of bFGF gene expression and tumor angiogenesis of orth otopic implantation of human gastric carcinoma by N-desulfated heparin]

OBJECTIVE: To investigate the effect of N-desulfated heparin on tumor metastasis, tumor angiogenesis and basic fibroblast growth factor(bFGF) gene expression of orthotopically implanted human gastric carcinoma in NOD-SCID mice. METHODS: Human gastric cancer SGC-7901 tissues were orthotopically implanted into the stomach of the NOD-SCID mice. Twenty mice were randomly divided into two groups which received either intravenous injection of 0.9% NaCl solution(0.9%NaCl solution group) or 10 mg/kg N-desulfated heparin (N-desulfated heparin group) twice a week for three weeks. Mice were sacrificed six weeks after tumor implantation. Tissues from stomach and other organs were obtained for histopathological evaluation. The intratumoral microvessel density (MVD) in tumor was evaluated immunohistochemically. Real time PCR was used to detect bFGF mRNA expression. RESULTS: The tumor metastasis rates were 9/10 in 0.9% NaCl solution group and 2/10 in N-desulfated heparin group(P<0.05).MVD was 9.1+/-3.4 in 0.9% NaCl solution group and 4.7+/-1.8 in N-desulfated heparin group (t=3.617,P<0.05). bFGF mRNA expression was lower in N-desulfated heparin group(2.60+/-0.56%)than that in 0.9% NaCl solution group(30.65+/-6.84%). CONCLUSION: N-desulfated heparin can inhibit the metastasis of gastric cancer through inhibiting tumor bFGF gene expression and tumor angiogenesis with no obvious anticoagulant activity.     

Inhibition of human immunodeficiency virus gene amplification by heparin.

Gene amplification of virus-specific sequences is widely used as a method to detect or confirm human immunodeficiency virus (HIV) infection. In this study we used an enzyme-linked affinity assay to quantify polymerase chain reaction products from whole blood, plasma, and separated mononuclear cells collected in the presence of four common anticoagulants: acid citrate dextrose, sodium EDTA, potassium oxalate, and sodium heparin. Attenuation of the product signal was observed after amplification of nucleic acid extraction from whole blood, washed mononuclear cells, and plasma from specimens collected in sodium heparin. These inhibitory effects on gene amplification could be reversed with heparinase. The addition of as little as 0.05 U of heparin completely inhibited amplification of an HLA-DQa sequence from placental DNA. We conclude that heparin can cause attenuation or inhibition of gene amplification. Acid citrate dextrose and EDTA, which lack inhibitory activity, are the most appropriate anticoagulants for clinical blood samples when polymerase chain reaction amplification is anticipated.     

Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: A gene therapy approach

We developed an in vivo gene therapy approach to characterize and optimize the anti-angiogenic activity of class I interferons (IFNs), using packaging cell lines producing an amphotropic LXSN-based retrovirus expressing either IFN-alpha1 (alpha1Am12), IFN-beta (betaAm12) murine cDNAs, or the vector alone (neoAm12). Pretreatment of endothelial-like Eahy926 cells in vitro with conditioned media (CM) from alpha1Am12 or betaAm12 cells for 48 hours significantly inhibited their migration and invasion as compared to neoAm12-CM-treated cells. betaAm12-CM also inhibited the formation of capillary-like structures on Matrigel by EAhy926 cells. In vivo, inclusion of the betaAm12 cells strongly inhibited, and alpha1Am12 partially inhibited, the angiogenic response in the Matrigel sponge model in both immune-competent and athymic nude mice. Electron microscopy showed a reduction of host cell infiltration in alpha1Am12- and betaAm12-containing sponges and reduction of invading tubular clefts of host cells as compared to controls. Finally, inoculation of either alpha1Am12 or betaAm12 cells (10%) along with a highly angiogenic Kaposi's sarcoma cell line (90%) resulted in a powerful reduction of tumor growth in nude mice in vivo, as did infection with the interferon-alpha-producing retroviruses. These data suggest that a gene therapy approach using class I interferons can effectively inhibit tumor angiogenesis and growth of vascular tumors.     

Tissue factor expression and angiogenesis in human prostate carcinoma

In tumors, the switch to the angiogenic phenotype is thought to be controlled by a balance of positive and negative angiogenic factors. Tissue factor (TF) produced by tumor cells has been implicated in the regulation of this "angiogenic switch" through its ability to concurrently induce the expression of angiogenic molecules such as vascular endothelial cell growth factor (VEGF), while inhibiting the expression of anti-angiogenic molecules such as thrombospondin 2. We have examined TF expression and its relationship to angiogenesis and tumor progression in human prostate carcinomas. Most of the prostate carcinoma specimens examined (73%; n = 67) express high levels of TF. Immunohistochemical analysis localized TF expression to the epithelial cells of malignant glands. TF expression was significantly correlated with tumor angiogenesis as measured by the microvessel density (MVD). In addition, TF expression was correlated with the preoperative PSA level, a strong predictor of recurrence in prostate carcinomas. Our findings show that TF expression by the malignant glands in prostate cancer is common and suggest a role for this molecule in regulating prostate cancer progression and angiogenesis.     

修饰的反义寡脱氧核苷酸对胰腺癌细胞生长和靶基因表达的抑…

观察修饰过的反义寡脱氧核苷酸对人胰腺癌细胞生长和靶基因表达的抑制作用。     

脑星形细胞瘤中bFGF及其受体对血管新生 和肿瘤细胞增殖的影响

目的：为探讨碱性纤维母细胞生长因子（ｂＦＧＦ）及其受体（ＦＧＦＲ－２）对人星形细胞瘤的血管新生及细胞增殖的作用。方法：彩和免疫组织化学方法,结果：发现ｂＦＧＦ及其受体,增殖细胞核抗原（ＰＣＮＡ）在瘤细胞及血管内皮细胞中均有表达,高级别星形细胞瘤的表达阳性率高于低级别者,ｂＦＧＦ在瘤细胞中的表达阳性率分别为与ＦＧＦＲ－２及ＰＣＮＡ的表达阳性率呈正相关关系（Ｐ〈０．０１,Ｐ〈０．０５）,ｂＦＧＦ及其受     

人肺癌相关抗原基因ALT04-AG表达抑制对人肺癌细胞株生长及基因表达谱的影响

目的探讨抑制人肺癌相关抗原基因ALT04-AG表达对细胞生长特性及相关基因表达的影响。方法重组反义ALT04-AGRNA真核表达质粒,经脂质体介导转染人肺癌细胞株(L78),以MTT、FCM法分析转染细胞生长特性,以Northern b lot、免疫组化染色及基因芯片技术检测相关基因的表达。结果构建了重组表达反义ALT04-AGRNA的真核表达质粒[pALT04-AG(as)],经该质粒转染及二氟甲基鸟氨酸(d ifluorom ethylorn ith ine,DFMO)处理的L78细胞均引起ALT04-AG表达下调及细胞的增殖抑制,后者还导致细胞凋亡比例增加。结论pALT04-AG(as)转染L78细胞或用DFMO抑制多胺生物合成,可通过对相关基因表达的调控促使L78细胞恶性表型逆转,而后者的作用更为广泛。本结果为探索肿瘤的诊断与治疗提供了有意义的线索。     

Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model

The nonreceptor protein tyrosine kinase Src is overexpressed in 70% of pancreatic adenocarcinomas. Here, we describe the effect of molecular and pharmacological down-regulation of Src on incidence, growth, and metastasis of pancreatic tumor cells in an orthotopic model. Src expression in L3.6pl human pancreatic tumor cells was reduced by stable expression of a plasmid encoding small interfering RNA (siRNA) to c-src. In stable siRNA clones, Src expression was reduced >80%, with no change in expression of the related kinases c-Yes and c-Lyn, and proliferation rates were similar in all clones. Phosphorylation of Akt and p44/42 Erk mitogen-activated protein kinase and production of VEGF and IL-8 in culture supernatants were also reduced (P < 0.005). On orthotopic implantation of varying cell numbers into nude mice, tumor incidence was unchanged; however, in the siRNA clones, large tumors failed to develop, and incidence of metastasis was significantly reduced, suggesting that c-Src activity is critical to tumor progression. To examine this possibility further, animals bearing established wild-type tumors were treated with the Src/Abl-selective inhibitor BMS-354825 (dasatinib). Tumor size was decreased, and incidence of metastases was significantly reduced in treated mice compared with controls. These results demonstrate that Src activation contributes to pancreatic tumor progression in this model, offering Src as a candidate for targeted therapy.